Skip to main content
NCBI home page
The Western Journal of Medicine logoLink to The Western Journal of Medicine
. 1988 Jul;149(1):37–39.

Prostacyclin Production Following In Vitro Mixing of Normal With Hemolytic-Uremic-Syndrome Serum

Richard L Siegler, Jean B Smith, Michael B Lynch, Syed F Mohammad
PMCID: PMC1026241  PMID: 3043896

Abstract

Serum from patients with the hemolytic-uremic syndrome (HUS) usually has a diminished ability to support the production of prostacyclin (prostaglandin [PG] I2). An impaired ability to produce this potent antiaggregatory substance could account for the thrombotic microangiopathy that is characteristic of the syndrome.

We did in vitro mixing experiments to determine if adding normal serum in various concentrations would improve the ability of HUS serum to support PGI2 production when incubated with cultured human endothelial cells. Mixing normal with HUS serum in a 1:2, 1:3, and 1:6 ratio generally enhanced the PGI2-supporting capacity of the HUS serum. Moreover, adding normal serum yielded a mixture whose supporting capacity was between the normal and the HUS serum's value, and the PGI2-supporting capacity could be predicted by calculating the weighted average value of the components of the mixture. There was a strong correlation between the calculated (predicted) and the actual experimental values (r = .95, P<.001).

Full text

PDF
37

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Chamone D. A., Proesmans W. C., Monnens L. A., Binda ki Muaka P., Vermylen J. G. Reversible deficient prostacyclin release in childhood hemolytic uremic syndrome. Int J Pediatr Nephrol. 1982 Mar;3(1):13–16. [PubMed] [Google Scholar]
  2. Feldhoff C. M., Luboldt W., Bussmann K., Schrör K. Plasma exchanges in frequently recurrent hemolytic-uremic syndrome in a child. Int J Pediatr Nephrol. 1983 Dec;4(4):239–242. [PubMed] [Google Scholar]
  3. Levin M., Elkon K. B., Nokes T. J., Buckle A. M., Dillon M. J., Hardisty R. M., Barratt T. M. Inhibitor of prostacyclin production in sporadic haemolytic uraemic syndrome. Arch Dis Child. 1983 Sep;58(9):703–708. doi: 10.1136/adc.58.9.703. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Remuzzi G., Marchesi D., Misiani R., Mecca G., de Gaetano G., Donati M. B. Familial deficiency of a plasma factor stimulating vascular prostacyclin activity. Thromb Res. 1979;16(3-4):517–525. doi: 10.1016/0049-3848(79)90098-7. [DOI] [PubMed] [Google Scholar]
  5. Remuzzi G., Mecca G., Livio M., de Gaetano G., Donati M. B., Pearson J. D., Gordon J. L. Prostacyclin generation by cultured endothelial cells in haemolytic uraemic syndrome. Lancet. 1980 Mar 22;1(8169):656–657. doi: 10.1016/s0140-6736(80)91153-8. [DOI] [PubMed] [Google Scholar]
  6. Remuzzi G., Misiani R., Marchesi D., Livio M., Mecca G., de Gaetano G., Donati M. B. Haemolytic-uraemic syndrome: deficiency of plasma factor(s) regulating prostacyclin activity? Lancet. 1978 Oct 21;2(8095):871–872. doi: 10.1016/s0140-6736(78)91573-8. [DOI] [PubMed] [Google Scholar]
  7. Remuzzi G., Misiani R., Marchesi D., Livio M., Mecca G., de Gaetano G., Donati M. D. Treatment of the hemolytic uremic syndrome with plasma. Clin Nephrol. 1979 Dec;12(6):279–284. [PubMed] [Google Scholar]
  8. Siegler R. L., Smith J. B., Lynch M. B., Mohammad S. F. In vitro prostacyclin production in the hemolytic-uremic syndrome. West J Med. 1986 Feb;144(2):165–168. [PMC free article] [PubMed] [Google Scholar]
  9. Stuart M. J., Spitzer R. E., Coppe D. Abnormal platelet and vascular prostaglandin synthesis in an infant with hemolytic uremic syndrome. Pediatrics. 1983 Jan;71(1):120–124. [PubMed] [Google Scholar]
  10. Wiles P. G., Solomon L. R., Lawler W., Mallick N. P., Johnson M. Inherited plasma factor deficiency in haemolytic-uraemic syndrome. Lancet. 1981 May 16;1(8229):1105–1106. doi: 10.1016/s0140-6736(81)92275-3. [DOI] [PubMed] [Google Scholar]

Articles from Western Journal of Medicine are provided here courtesy of BMJ Publishing Group

RESOURCES